Todays Report: The Fresenius Medical Care AG (FMS) Issues Quarterly Earnings Results

The Fresenius Medical Care AG (FMS) Issues Quarterly  Earnings Results

Fresenius Medical Care AG (NYSE:FMS) released its quarterly earnings data on Thursday. The company reported $1.09 EPS for the quarter, beating the consensus estimate of $0.52 by $0.57. The business had revenue of $4.60 billion for the quarter, compared to the consensus estimate of $4.55 billion. Fresenius Medical Care AG had a net margin of 6.67% and a return on equity of 10.22%. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.93 EPS.

Fresenius Medical Care AG (NYSE:FMS) opened at 40.76 on Monday. Fresenius Medical Care AG has a 52-week low of $38.71 and a 52-week high of $47.52. The firm’s 50-day moving average is $42.76 and its 200-day moving average is $43.59. The firm has a market capitalization of $24.96 billion, a PE ratio of 21.29 and a beta of 0.58.

Hedge funds have recently added to or reduced their stakes in the company. Cambiar Investors LLC boosted its stake in Fresenius Medical Care AG by 5.2% in the second quarter. Cambiar Investors LLC now owns 2,333,733 shares of the company’s stock worth $101,681,000 after buying an additional 114,840 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Fresenius Medical Care AG by 1.5% in the first quarter. JPMorgan Chase & Co. now owns 134,551 shares of the company’s stock worth $5,930,000 after buying an additional 1,950 shares during the last quarter. Mariner Wealth Advisors LLC bought a new stake in Fresenius Medical Care AG during the first quarter worth $331,000. Rothschild Asset Management Inc. bought a new stake in Fresenius Medical Care AG during the second quarter worth $340,000. Finally, Independent Portfolio Consultants Inc. boosted its stake in Fresenius Medical Care AG by 2.2% in the second quarter. Independent Portfolio Consultants Inc. now owns 6,155 shares of the company’s stock worth $268,000 after buying an additional 130 shares during the last quarter. 2.49% of the stock is currently owned by institutional investors.

Several research firms have recently commented on FMS. Citigroup Inc. raised shares of Fresenius Medical Care AG from a “neutral” rating to a “buy” rating in a report on Tuesday, September 6th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a report on Tuesday, September 13th. Berenberg Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a report on Tuesday, August 9th. SunTrust Banks Inc. set a $48.00 price objective on shares of Fresenius Medical Care AG and gave the company a “buy” rating in a report on Thursday, October 13th. Finally, HSBC reaffirmed a “hold” rating on shares of Fresenius Medical Care AG in a report on Tuesday, October 18th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the stock. Fresenius Medical Care AG has a consensus rating of “Hold” and an average price target of $45.00.

About Fresenius Medical Care AG

Related posts

Leave a Comment